Jefferies analyst Research Report) yesterday and set a price target of $90.00. The company’s shares closed yesterday at $56.33.
According to TipRanks, Tsai is a 3-star analyst with an average return of 1.6% and a 47.37% success rate. Tsai covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Xenon, and VistaGen Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intra-Cellular Therapies with a $71.63 average price target, implying a 27.16% upside from current levels. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $75.00 price target.
ITCI market cap is currently $5.31B and has a P/E ratio of (15.55).
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer’s disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer’s disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
Read More on ITCI:
- Jackson Financial Incorporation (JXN) Receives a Buy from Jefferies
- Jefferies Sticks to Its Buy Rating for Arch Resources (ARCH)
- Crawford United Corporation Announces Second Quarter 2022 Results
- Analysts Offer Insights on Healthcare Companies: Astria Therapeutics (ATXS) and Karuna Therapeutics (KRTX)
- Wall Street Analysts Are Bullish on Top Technology Picks